EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Alcian blue‐positive stromal phenotype in basal cell carcinoma is associated with progression on first‐line hedgehog inhibitors

Viola K DeTemple iD, Rudolf Stadler, Sabine Bredemeier, Sungyoung Chung, Katrin Schaper-Gerhardt, Mareike Alter, Yenny Angela, Henner Stege, Ulrike Leiter, Jan Ohletz, Elisabeth Livingstone, Imke von Wasielewski und 6 weitere

The Journal of Pathology: Clinical Research · 2026

DOI: 10.1002/2056-4538.70074 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift The Journal of Pathology: Clinical Research, 2026. Verfasst von Viola K DeTemple und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Johannes Wesling Medical Center Minden, Ruhr-University Bochum, Bochum, Germany. Hauptthemen laut MEDLINE: Anilides, Antineoplastic Agents, Basal Cell Carcinoma, Hedgehog Proteins. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ruhr-Universität Bochum.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Basal cell carcinoma (BCC) is the most frequent malignancy in fair‐skinned populations. Although curable in most cases, approximately 4% of patients develop locally advanced or metastatic disease (advBCC) requiring systemic therapy. Hedgehog pathway inhibitors (HHIs; vismodegib/sonidegib) constitute standard first‐line treatment, yet individual responses vary and no histopathological biomarker predicting therapeutic outcome exists. We conducted a retrospective, multicenter analysis of 70 BCCs encompassing clinically common and advanced stages. Routine hematoxylin and eosin and Alcian blue (AB; pH 2.5) staining was evaluated using a 17‐parameter, numerically encoded histopathology matrix spanning tumor morphology, stromal composition, and immune contexture. Data were mapped by unsupervised hierarchical clustering. Distinct AB staining patterns were observed: superficial and nodular BCCs typically exhibited an AB‐positive peritumoral border, whereas infiltrative and sclerosing subtypes displayed a diffuse AB‐positive desmoplastic stroma. The latter also correlated with advanced EADO clinical stages (correlation coefficients 0.46–0.48; p < 0.001). In a subset of 30 advBCCs obtained before or during HHI therapy, AB‐positive stroma was the only parameter independently associated with shorter progression‐free survival (multivariable hazard ratio = 23.8; 95% CI 4.02–141.3; p < 0.001). Established clinical or histological features failed to associate with outcome. Our findings identify diffuse AB‐positive stroma as a readily detectable feature of histologically aggressive BCC and as a candidate biomarker associated with progression under HHI treatment. Because AB staining is routine, inexpensive, and easily standardized, this phenotype represents an immediately implementable readout for prospective validation and a potential link between extracellular‐matrix remodeling and therapy resistance in BCC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AnilidesAntineoplastic AgentsBasal Cell CarcinomaHedgehog ProteinsPyridinesSkin NeoplasmsStromal CellsAgedAged, 80 and overFemaleHumansMaleMiddle AgedBiomarkers, TumorDisease ProgressionPhenotypeRetrospective StudiesAlcian BlueBiphenyl Compounds

Stichwörter der Autor:innen

Alcian blue stainingbasal cell carcinomabiomarkersdesmoplasiaglycosaminoglycanshedgehog inhibitorssonidegibtherapy resistancetumor stromavismodegib

Substanzen

AnilidesAntineoplastic AgentsBiomarkers, TumorHedgehog ProteinsHhAntag691PyridinessonidegibAlcian BlueBiphenyl Compounds

Autor:innen und Institutionen

  • Department of Dermatology, Johannes Wesling Medical Center Minden, Ruhr-University Bochum, Bochum, Germany.
  • Department of Dermatology, University Hospital Mainz, Mainz, Germany.
  • Division of Dermatooncology, Department of Dermatology, University Medical Center, Tuebingen, Germany.
  • Department of Dermatology, Vivantes MVZ GmbH, Berlin-Spandau, Germany.
  • Department of Dermatology, University Hospital Essen, Essen, Germany.
  • Skin Cancer Research, German Cancer Consortium (DKTK), Partner Site Essen/Duesseldorf, Duesseldorf, Germany.

ORCID-Profile: Viola K DeTemple, Christina H Scheel

Förderung

  • Ruhr-Universität Bochum

Zitieren

APA

DeTemple, V. K., Stadler, R., Bredemeier, S., Chung, S., Schaper-Gerhardt, K., Alter, M., Angela, Y., Stege, H., Leiter, U., Ohletz, J., Livingstone, E., von Wasielewski, I., Hassel, J. C., Huynh, J., Gebhardt, C., Pföhler, C., Gutzmer, R., & Scheel, C. H. (2026). Alcian blue‐positive stromal phenotype in basal cell carcinoma is associated with progression on first‐line hedgehog inhibitors. The Journal of Pathology: Clinical Research. https://doi.org/10.1002/2056-4538.70074

Vancouver

DeTemple VK, Stadler R, Bredemeier S, Chung S, Schaper-Gerhardt K, Alter M, et al. Alcian blue‐positive stromal phenotype in basal cell carcinoma is associated with progression on first‐line hedgehog inhibitors. The Journal of Pathology: Clinical Research. 2026. doi:10.1002/2056-4538.70074

BibTeX
@article{DeTemple2026,
  author = {DeTemple, Viola K and Stadler, Rudolf and Bredemeier, Sabine and Chung, Sungyoung and Schaper-Gerhardt, Katrin and Alter, Mareike and Angela, Yenny and Stege, Henner and Leiter, Ulrike and Ohletz, Jan and Livingstone, Elisabeth and von Wasielewski, Imke and Hassel, Jessica C and Huynh, Julia and Gebhardt, Christoffer and Pföhler, Claudia and Gutzmer, Ralf and Scheel, Christina H},
  title = {Alcian blue‐positive stromal phenotype in basal cell carcinoma is associated with progression on first‐line hedgehog inhibitors},
  journal = {The Journal of Pathology: Clinical Research},
  year = {2026},
  doi = {10.1002/2056-4538.70074}
}
Kostenlos starten →